Novo Nordisk Sues USPTO Over AERx Applications

Law360, New York (November 17, 2006, 12:00 AM EST) -- Disgruntled after the U.S. Patent and Trademark Office rejected numerous applications for patents relating to its insulin delivery system, Danish pharmaceutical giant Novo Nordisk AS has sued the director of the agency, Jon Dudas.

The USPTO has rejected applications from Novo Nordisk for patents relating to its AERx inhaled insulin delivery system, claiming that the patents didn’t bring anything new to the table.

The pharmaceutical giant, however, claims that the office misinterpreted data, evidence and legislation, according to Danish newspaper Børsen.

Novo Nordisk said it had...
To view the full article, register now.